Golimumab was effective in maintaining clinical improvement through year-@ ( ACR@ : @-@ @ % , DAS@-CRP : @-@ @ % for randomised patients ; PASI@ : @-@ @ % among randomised patients with @ % body surface area involvement ) and inhibiting radiographic progression ( mean changes in PsA-modified SHS : @-@ @ ) among patients with radiographic data .